NASDAQ: XLO

Xilio Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for XLO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Xilio Therapeutics, Inc. (NASDAQ: XLO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:50 UTC.

Key facts

Valuation	8-K 2026-06-12
Return on equity	-99.33%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-02

2026-10-02CHIEF MEDICAL OFFICERStock Option (right to buy)Award105,000—
2026-06-12DirectorStock Option (right to buy)Award5,000—
2026-06-12DirectorStock Option (right to buy)Award5,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Bain Capital Life Sciences Investors, LLC664,021$6.36M0.0%
GILEAD SCIENCES, INC.650,389$6.23M0.0%
ORBIMED ADVISORS LLC592,300$5.67MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-11-25Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-01-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-09-05Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
globenewswire.com2026-06-29
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
globenewswire.com2026-04-17
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Xilio Therapeutics, Inc. do?

Xilio Therapeutics, Inc. is a biotechnology company, listed on NASDAQ as XLO.

When did XLO last file with the SEC?

Xilio Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:50 UTC. This page is also available as JSON at /api/data?ticker=XLO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for XLO and 5,000+ tickers.

Create a free account — keep XLO

For your agent

GET /api/data?ticker=XLO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt